Sanofi to test Parkinson's drug with Michael J. Fox Foundation

PARIS Thu Apr 19, 2012 11:27am IST

Related Topics

Stocks

   

PARIS (Reuters) - French drugmaker Sanofi said on Thursday it would collaborate with the Michael J. Fox Foundation to test an early- stage experimental treatment for Parkinson's disease.

Under the terms of the collaboration, MJFF will sponsor a phase I clinical trial to study the safety and tolerability of Sanofi's AVE8112, a drug that has shown promise in preclinical tests as a therapy for some of the psychiatric symptoms of the disease.

Parkinson's disease is a brain disorder that leads to shaking and difficulty with walking as well as mood changes and impaired memory.

All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. Further development plans will be based on the results of the study, Sanofi said.

Patient enrollment in the study, which will be conducted in the U.S., is expected to begin later this year.

(Reporting by Elena Berton; Editing by Nina Sovich)

FILED UNDER:

Ebola Outbreak

Reuters Showcase

IS Claim

IS Claim

Islamic State says beheads second Japanese hostage.  Full Article 

Ukraine Crisis

Ukraine Crisis

Death toll mounts in Ukraine fighting after peace talks fail.  Full Article 

Fifth Title

Fifth Title

Djokovic reigns supreme at Australian Open.  Full Article 

Journalist Freed

Journalist Freed

Jailed Al Jazeera journalist Peter Greste leaves Egypt for Australia.  Full Article 

Reuters Poll

Reuters Poll

RBI seen holding rates steady on Tuesday, minority of analysts expect cut.  Full Article 

Doubles Title

Doubles Title

Hingis wins Australian Open mixed doubles title with Paes.  Full Article 

Houston's Daughter

Houston's Daughter

Bobbi Kristina Brown revived after found unresponsive in tub  Full Article 

Supply Glut

Supply Glut

Sugar mills seek govt help to dispose of supply surplus.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage